Article

Daily Medication Pearl: Efgartigimod alfa-fcab (Vyvgart)

Efgartigimod alfa-fcab (Vyvgart) is a human immunoglobulin G1 antibody fragment indicated for the treatment of generalized myasthenia gravis.

Medication Pearl of the Day: Efgartigimod alfa-fcab (Vyvgart)

Indication: Efgartigimod alfa-fcab (Vyvgart)is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody positive.

Insight:

  • Dosing: The recommended dosage is 10 mg/kg administered as an intravenous infusion over 1 hour once weekly for 4 weeks.
  • Dosage forms: Injection 400 mg in 20 mL (20 mg/mL) single-dose vial.
  • Adverse events: Most common adverse reactions (≥ 10%) in patients treated with gMG are respiratory tract infections, headache, and urinary tract infection.
  • Mechanism of action: Efgartigimod alfa-fcab is a human immunoglobulin G1 (IgG1) antibody fragment that binds to the neonatal Fc receptor, resulting in the reduction of circulating IgG.
  • Manufacturer: Argenx

Sources:

vyvgart-prescribing-information.pdf (argenx.com)

Buy Vyvgart (efgartigimod alfa-fcab) Online • Price & Costs | TheSocialMedwork

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com